AstraZeneca to sell Ohio site to biotech firm Resilience

The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski

Nov 29 (Reuters) - AstraZeneca (AZN.L) is selling its West Chester manufacturing site in Ohio in the United States to biomanufacturing company National Resilience Inc, the company said on Tuesday.

The London-listed drugmaker expects to complete the sale in the first quarter of 2023.

Reporting by Muhammed Husain in Bengaluru; Editing by Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles.